News & Updates

Show Multimedia Only

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

30 May 2025 by

Findings from the phase III ELATIVE^® trial demonstrate that the peroxisome proliferator-activated receptor (PPAR) agonist elafibranor improves fatigue in individuals with primary biliary cholangitis (PBC), with limited correlation with pruritus.

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

30 May 2025

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

29 May 2025 by

IBP-9414, a live biotherapeutic product (LBP), delivers gastrointestinal (GI) and mortality benefits in very low birth weight (VLBW) infants (BW 500–1,500g) born between 23 and 32 weeks gestational age in the phase III Connection study presented at PAS 2025.

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

29 May 2025

10-year data reflect teduglutide efficacy for SBS-IF

28 May 2025 by

An interim analysis of a real-world study reporting up to 10 years of follow-up data shows that teduglutide, a human glucagon-like peptide-2 analogue, can provide long-term reductions in parenteral nutrition and/or intravenous fluid (PN/IV) requirements and shorter time to achieve enteral autonomy in adults with short bowel syndrome-associated intestinal failure (SBS-IF).

10-year data reflect teduglutide efficacy for SBS-IF

28 May 2025

Healthy diet helps prevent diverticulitis in women

27 May 2025

Women who adhere to a healthy dietary pattern have a reduced risk of incident diverticulitis, reports a study. Eating nuts and seeds also does not significantly increase such risk.

Healthy diet helps prevent diverticulitis in women

27 May 2025

FMT bodes well for AMR

27 May 2025 by

The PROFIT trial turns waste into gains by showing how faecal microbiota transplantation (FMT) can combat antimicrobial resistance (AMR) in patients with liver cirrhosis.

FMT bodes well for AMR

27 May 2025

Seladelpar improves cholestatic, liver injury markers in patients with PBC, cirrhosis

27 May 2025 by

Treatment with seladelpar led to improvements in markers of cholestasis and liver injury in patients with primary biliary cholangitis (PBC) and compensated cirrhosis, according to an additional analysis of the RESPONSE trial presented at DDW 2025.

Seladelpar improves cholestatic, liver injury markers in patients with PBC, cirrhosis

27 May 2025

Etrasimod shows promise in eosinophilic oesophagitis

26 May 2025

In the treatment of eosinophilic oesophagitis, the use of etrasimod is well tolerated and results in sustained histological and endoscopic improvements and symptom reduction, according to the results of a phase II study.

Etrasimod shows promise in eosinophilic oesophagitis

26 May 2025

Superior IBD control achieved with biomarker-guided therapy standard care

26 May 2025 by

Biomarker-informed molecular guidance improves anti-TNF therapy outcomes in patients with inflammatory bowel disease (IBD), increasing the likelihood of achieving disease control when compared with standard “best care,” as shown in the GUIDE-IBD trial.

Superior IBD control achieved with biomarker-guided therapy standard care

26 May 2025

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

26 May 2025 by

The galectin-3 (Gal3) inhibitor belapectin, given at the established 2-mg dose, demonstrates its treatment potential for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension (PH) in the phase IIb/III NAVIGATE trial.

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

26 May 2025

Full-spectrum microbiome drug for IBS with constipation clears phase II trial

25 May 2025 by

The next-generation oral full-spectrum microbiome drug EBX-102-02 appears to have an acceptable safety profile in patients with irritable bowel syndrome with constipation (IBS-C) while yielding improvements in symptom severity, abdominal pain, and stool consistency, according to the results of the phase IIa TrIuMPH* study.

Full-spectrum microbiome drug for IBS with constipation clears phase II trial

25 May 2025

News & Updates

Filter by Specialty:

Specialty:

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

10-year data reflect teduglutide efficacy for SBS-IF

10-year data reflect teduglutide efficacy for SBS-IF

Healthy diet helps prevent diverticulitis in women

Healthy diet helps prevent diverticulitis in women

FMT bodes well for AMR

FMT bodes well for AMR

Seladelpar improves cholestatic, liver injury markers in patients with PBC, cirrhosis

Seladelpar improves cholestatic, liver injury markers in patients with PBC, cirrhosis

Etrasimod shows promise in eosinophilic oesophagitis

Etrasimod shows promise in eosinophilic oesophagitis

Superior IBD control achieved with biomarker-guided therapy standard care

Superior IBD control achieved with biomarker-guided therapy standard care

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

Full-spectrum microbiome drug for IBS with constipation clears phase II trial

Full-spectrum microbiome drug for IBS with constipation clears phase II trial